Dr Fiona Thomson

  • Director of Translational Pharmacology Laboratory/ Senior Research Fellow (Translational Research Centre)
  • Affiliate (Veterinary Medicine Undergraduate School)

Biography

•    Director/Senior Research Fellow (Translational Pharmacology Laboratory)
•    Telephone 0141 330 4810
•    Email: Fiona.Thomson@glasgow.ac.uk
•    ORCID ID: https://orcid.org/0000-0002-8987-536


Research interests

The Translational Pharmacology Laboratory (TPL) aims to translate novel discoveries from basic laboratory research into patients by exploring novel anti-cancer therapies within clinical trials.  Our research is focused on the discovery and application of biomarkers to improve our understanding of drug action and patient response. By applying state-of the-art technologies, the TPL aims to develop novel strategies for molecular profiling and monitoring of pharmacodynamic biomarkers in tumour, blood and other ‘surrogate’ tissue sample types obtained from cancer patients. Our ultimate aim is to develop optimised, personalised treatments with improved therapeutic benefit for cancer patients.
 
As a key component of the Glasgow Experimental Cancer Medicine Centre (ECMC), the TPL works in close collaboration with researchers from CRUK’s Clinical Trials Unit, Glasgow and from the Beatson West of Scotland Cancer Centre.  The TPL is typically involved in biomarker discovery for more than a dozen early-phase oncology clinical trials at any given time. The TPL is one of only four UK laboratories awarded funding by CRUK’s Centre for Drug Development (CRUK-CDD) as a ‘CRUK Centre of Biomarker Excellence’.
 


Publications

List by: Type | Date

Jump to: 2019 | 2017 | 2016 | 2014 | 2013 | 2011 | 2010 | 2009 | 2008 | 2007 | 2005 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991
Number of items: 41.

2019

Horne, G. et al. (2019) A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease. Leukemia, (Accepted for Publication)

Veal, G. J., Amankwatia, E. B., Paludetto, M.-N., Möcklinghoff, T., Thomson, F. , André, N., Ciccolini, J. and Chatelut, E. (2019) Pharmacodynamic therapeutic drug monitoring for cancer: challenges, advances, and future opportunities. Therapeutic Drug Monitoring, 41(2), pp. 142-159. (doi:10.1097/FTD.0000000000000606) (PMID:30883508)

2017

Kutchukian, P. S. et al. (2017) Iterative focused screening with biological fingerprints identifies selective Asc-1 inhibitors distinct from traditional high throughput screening. ACS Chemical Biology, 12(2), pp. 519-527. (doi:10.1021/acschembio.6b00913) (PMID:28032990)

2016

Tsim, S. et al. (2016) Diagnostic and prognostic biomarkers in the rational assessment of mesothelioma (DIAPHRAGM) study: protocol of a prospective, multi-centre, observational study. BMJ Open, 6(11), e013324. (doi:10.1136/bmjopen-2016-013324) (PMID:27884852) (PMCID:PMC5168514)

2014

Eddins, D., Hamill, T. G., Puri, V., Cannon, C. E., Vivian, J. A., Sanabria-Bohórquez, S. M., Cook, J. J., Morrow, J. A., Thomson, F. and Uslaner, J. M. (2014) The relationship between glycine transporter 1 occupancy and the effects of the glycine transporter 1 inhibitor RG1678 or ORG25935 on object retrieval performance in scopolamine impaired rhesus monkey. Psychopharmacology, 231(3), pp. 511-519. (doi:10.1007/s00213-013-3260-0) (PMID:24051602)

2013

Neale, S.A., Copeland, C.S., Uebele, V.N., Thomson, F.J. and Salt, T.E. (2013) Modulation of hippocampal synaptic transmission by the kynurenine pathway member xanthurenic acid and other VGLUT inhibitors. Neuropsychopharmacology, 38(6), pp. 1060-1067. (doi:10.1038/npp.2013.4) (PMID:23303071) (PMCID:PMC3629405)

2011

Baker, J. et al. (2011) Identification and optimisation of novel sulfonamide, selective vasopressin V1B receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 21(12), pp. 3603-3607. (doi:10.1016/j.bmcl.2011.04.104)

Napier, S. et al. (2011) The discovery of novel 8-azabicyclo[3.2.1]octan-3-yl)-3-(4-chlorophenyl) propanamides as vasopressin V1A receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 21(10), pp. 3163-3167. (doi:10.1016/j.bmcl.2011.02.096)

Napier, S. E. et al. (2011) Synthesis and SAR studies of novel 2-(4-oxo-2-aryl-quinazolin-3(4H)-yl)acetamide vasopressin V1b receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 21(6), pp. 1871-1875. (doi:10.1016/j.bmcl.2010.12.081)

Brown, A. R. et al. (2011) Discovery and optimisation of a selective non-steroidal glucocorticoid receptor antagonist. Bioorganic and Medicinal Chemistry Letters, 21(1), pp. 137-140. (doi:10.1016/j.bmcl.2010.11.054) (PMID:21129964)

Eddins, D. et al. (2011) The glycine transporter 1 inhibitors RG1678 and ORG25935 attenuate a scopolamine-induced impairment in object retrieval performance in adult rhesus macaques. Society for Neuroscience Abstract Viewer and Itinerary Planner, 2011.

Morrow, J.A., Gilfillan, R., McAlpine, C., Neale, S.A., Porter, A., Smith, L.H. and Thomson, F. (2011) Functional characterization of structurally distinct classes of Glycine Transporter type 1 (GlyT1) inhibitors. Society for Neuroscience Abstract Viewer and Itinerary Planner, 2011.

Spiga, F., Knight, D. M., Droste, S. K., Conway-Campbell, B., Kershaw, Y., MacSweeney, C. P., Thomson, F. J. , Craighead, M., Peeters, B. W.M.M. and Lightman, S. L. (2011) Differential effect of glucocorticoid receptor antagonists on glucocorticoid receptor nuclear translocation and DNA binding. Journal of Psychopharmacology, 25(2), pp. 211-221. (doi:10.1177/0269881109348175) (PMCID:PMC4984974)

Thomson, F. , Dunnigan, J., Gilfillan, R., Morrow, J.A. and Porter, A. (2011) Characterization of the receptor binding properties of structurally distinct classes of glycine transporter type 1 (glyt1) inhibitor. Society for Neuroscience Abstract Viewer and Itinerary Planner, 2011.

2010

Letourneau, J. J. et al. (2010) Identification and optimization of novel 2-(4-oxo-2-aryl-quinazolin-3(4H)-yl)acetamide vasopressin V3 (V1b) receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 20(18), pp. 5394-5397. (doi:10.1016/j.bmcl.2010.07.118)

Reid, M. et al. (2010) The discovery and SAR of indoline-3-carboxamides—A new series of 5-HT6 antagonists. Bioorganic and Medicinal Chemistry Letters, 20(12), pp. 3713-3716. (doi:10.1016/j.bmcl.2010.04.085)

2009

Spiga, F., Harrison, L.R., Wood, S., Knight, D.M., MacSweeney, C.P., Thomson, F. , Craighead, M. and Lightman, S.L. (2009) Blockade of the V1b receptor reduces ACTH, but not corticosterone secretion induced by stress without affecting basal hypothalamic-pituitary-adrenal axis activity. Journal of Endocrinology, 200(3), pp. 273-283. (doi:10.1677/JOE-08-0421)

Spiga, F., Harrison, L. R., MacSweeney, C. P., Thomson, F. J. , Craighead, M. and Lightman, S. L. (2009) Effect of vasopressin 1b receptor blockade on the hypothalamic-pituitary-adrenal response of chronically stressed rats to a heterotypic stressor. Journal of Endocrinology, 200(3), pp. 285-291. (doi:10.1677/JOE-08-0425) (PMID:19074473)

2008

Thomson, F. and Craighead, M. (2008) Innovative approaches for the treatment of depression: targeting the HPA axis. Neurochemical Research, 33(4), pp. 691-707. (doi:10.1007/s11064-007-9518-3) (PMID:17960478)

Spiga, E., Harrison, L.R., MacSweeney, C.P., Thomson, F.J. , Craighead, M. and Lightman, S.L. (2008) Blockage of the vasopressin V1b receptor prevents the chronic restraint-induced sensitization of the ACTH response to acute noise. European Neuropsychopharmacology, 18, S28. (doi:10.1016/S0924-977X(08)70034-8)

Spiga, F., Harrison, L. R., Wood, S. A., MacSweeney, C. P., Thomson, F. .J. , Craighead, M., Grassie, M. and Lightman, S. L. (2008) Effect of the glucocorticoid receptor antagonist Org 34850 on fast and delayed feedback of corticosterone release. Journal of Endocrinology, 196(2), pp. 323-330. (doi:10.1677/JOE-07-0503) (PMID:18252955)

Craighead, M., Milne, R., Campbell-Wan, L., Watson, L., Presland, J., Thomson, F. J. , Marston, H. M. and MacSweeney, C. P. (2008) Characterization of a novel and selective V1B receptor antagonist. Progress in Brain Research, 170, pp. 527-535. (doi:10.1016/S0079-6123(08)00440-8) (PMID:18655906)

2007

Spiga, F., Harrison, L.R., Wood, S.A., Atkinson, H.C., MacSweeney, C.P., Thomson, F. , Craighead, M., Grassie, M. and Lightman, S.L. (2007) Effect of the glucocorticoid receptor antagonist Org 34850 on basal and stress-induced corticosterone secretion. Journal of Neuroendocrinology, 19(11), pp. 891-900. (doi:10.1111/j.1365-2826.2007.01605.x) (PMID:17927667)

2005

Price, M. R. et al. (2005) Allosteric modulation of the cannabinoid CB1 receptor. Molecular Pharmacology, 68(5), pp. 1484-1495. (doi:10.1124/mol.105.016162) (PMID:16113085)

1997

Thomson, F. J. , Jess, T. J., Moyes, C., Plevin, R. and Gould, G. (1997) Characterization of the intracellular signalling pathways that underlie growth-factor-stimulated glucose transport in Xenopus oocytes: evidence for ras- and rho-dependent pathways of phosphatidylinositol 3-kinase activation. Biochemical Journal, 325(3), pp. 637-643. (PMID:9271083)

1996

Jess, T. J., Belham, C. M., Thomson, F. J. , Scott, P. H., Plevin, R. J. and Gould, G. (1996) Phosphatidylinositol 3′-kinase, but not p70 ribosomal S6 kinase, is involved in membrane protein recycling: Wortmannin inhibits glucose transport and downregulates cell-surface transferrin receptor numbers independently of any effect on fluid-phase endocytosis in fibroblasts. Cellular Signalling, 8(4), pp. 297-304. (doi:10.1016/0898-6568(96)00054-X) (PMID:8842531)

Livingstone, C. et al. (1996) Hormonal regulation of the insulin-responsive glucose transporter, GLUT4: some recent advances. Proceedings of the Nutrition Society, 55(1B), pp. 179-190. (doi:10.1079/PNS19960019) (PMID:8832790)

Thomson, F. j. , Moyes, C., Scott, P. H., Plevin, R. and Gould, G. W. (1996) Lysophosphatidic acid stimulates glucose transport in Xenopus oocytes via a phosphatidylinositol 3'-kinase with distinct properties. Biochemical Journal, 316(1), pp. 161-166. (PMID:8645200) (PMCID:PMC1217317)

1995

Gould, G. W. , Cuenda, A., Thomson, F. J. and Cohen, P. (1995) The activation of distinct mitogen-activated protein kinase cascades is required for the stimulation of 2-deoxyglucose uptake by interleukin-1 and insulin-like growth factor-1 in KB cells. Biochemical Journal, 311(3), pp. 735-738. (PMID:7487926)

Thomson, F. J. and Clark, M. A. (1995) Purification of a phosphatidic-acid-hydrolysing phospholipase A2 from rat brain. Biochemical Journal, 306(1), pp. 305-309. (PMID:7864824)

1994

Thomson, F.J. , Perkins, L., Ahern, D. and Clark, M. (1994) Identification and characterization of a lysophosphatidic acid receptor. Molecular Pharmacology, 45(4), pp. 718-723. (PMID:8183251)

Perkins, L. M., Ramirez, F. E., Kumar, C. C., Thomson, F. J. and Clark, M. A. (1994) Activation of serum response element-regulated genes by lysophosphatidic acid. Nucleic Acids Research, 22(3), pp. 450-452. (doi:10.1093/nar/22.3.450) (PMID:8127683) (PMCID:PMC523602)

Thomson, F.J. , Johnson, M.S., Mitchell, R. and Wolbers, B. (1994) Evidence for a role of phospholipase A2 in the mechanism of LHRH priming in rat anterior pituitary tissue. Journal of Endocrinology, 141(1), pp. 15-31. (doi:10.1677/joe.0.1410015) (PMID:8014598)

Thomson, F. J. and Clark, M. A. (1994) Purification of a lysophosphatidic acid-hydrolysing lysophospholipase from rat brain. Biochemical Journal, 300(2), pp. 457-461. (doi:10.1042/bj3000457) (PMID:8002951)

1993

Thomson, F.J. , Johnson, M.S., MacEwan, D.J. and Mitchell, R. (1993) Oestradiol-17 modulates the actions of pharmacologically distinct forms of protein kinase C in rat anterior pituitary cells. Journal of Endocrinology, 136(1), pp. 105-117. (doi:10.1677/joe.0.1360105) (PMID:8429266)

Johnson, M.S., Thomson, F.J. , MacEwan, D.J. and Mitchell, R. (1993) The involvement of dihydropyridine-sensitive calcium channels in phorbol ester-induced luteinizing hormone and growth hormone release. Molecular and Cellular Endocrinology, 95(1-2), pp. 31-41. (doi:10.1016/0303-7207(93)90026-G) (PMID:7694878)

MacEwan, D. J., Mitchell, R., Johnson, M. S., Thomson, F. J. , Lutz, E. M., Clegg, R. A. and Connor, K. (1993) Evidence that protein kinase Cα has reduced affinity towards 1,2-dioctanoyl-sn-glycerol: the effects of lipid activators on phorbol ester binding and kinase activity. European Journal of Pharmacology: Molecular Pharmacology, 246(1), pp. 9-18. (doi:10.1016/0922-4106(93)90003-R)

Thomson, F. J. , Johnson, M. S., Mitchell, R., Wolbers, W.B., Ison, A. J. and MacEwan, D. J. (1993) The differential effects of protein kinase C activators and inhibitors on rat anterior pituitary hormone release. Molecular and Cellular Endocrinology, 94(2), pp. 223-234. (doi:10.1016/0303-7207(93)90171-F) (PMID:8224525)

Thomson, F. J. and Mitchell, R. (1993) Differential involvement of phospholipase A2 in phorbol ester-induced luteinizing hormone and growth hormone release from rat anterior pituitary tissue. Molecular and Cellular Endocrinology, 95(1-2), pp. 75-83. (doi:10.1016/0303-7207(93)90031-E) (PMID:8243810)

1992

Johnson, M. S., Mitchell, R. and Thomson, F. J. (1992) The priming effect of luteinizing hormone-releasing hormone (LHRH) but not LHRH-induced gonadotropin release, can be prevented by certain protein kinase C inhibitors. Molecular and Cellular Endocrinology, 85(3), pp. 183-193. (doi:10.1016/0303-7207(92)90257-7) (PMID:1634016)

1991

MacEwan, D. J., Mitchell, R., Thomson, F. J. and Johnson, M. S. (1991) Inhibition of depolarisation-induced calcium influx into GH3 cells by arachidonic acid: the involvement of protein kinase C. Biochimica et Biophysica Acta: Molecular Cell Research, 1094(3), pp. 346-354. (doi:10.1016/0167-4889(91)90096-G) (PMID:1911881)

This list was generated on Fri Dec 6 02:39:29 2019 GMT.
Number of items: 41.

Articles

Horne, G. et al. (2019) A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease. Leukemia, (Accepted for Publication)

Veal, G. J., Amankwatia, E. B., Paludetto, M.-N., Möcklinghoff, T., Thomson, F. , André, N., Ciccolini, J. and Chatelut, E. (2019) Pharmacodynamic therapeutic drug monitoring for cancer: challenges, advances, and future opportunities. Therapeutic Drug Monitoring, 41(2), pp. 142-159. (doi:10.1097/FTD.0000000000000606) (PMID:30883508)

Kutchukian, P. S. et al. (2017) Iterative focused screening with biological fingerprints identifies selective Asc-1 inhibitors distinct from traditional high throughput screening. ACS Chemical Biology, 12(2), pp. 519-527. (doi:10.1021/acschembio.6b00913) (PMID:28032990)

Tsim, S. et al. (2016) Diagnostic and prognostic biomarkers in the rational assessment of mesothelioma (DIAPHRAGM) study: protocol of a prospective, multi-centre, observational study. BMJ Open, 6(11), e013324. (doi:10.1136/bmjopen-2016-013324) (PMID:27884852) (PMCID:PMC5168514)

Eddins, D., Hamill, T. G., Puri, V., Cannon, C. E., Vivian, J. A., Sanabria-Bohórquez, S. M., Cook, J. J., Morrow, J. A., Thomson, F. and Uslaner, J. M. (2014) The relationship between glycine transporter 1 occupancy and the effects of the glycine transporter 1 inhibitor RG1678 or ORG25935 on object retrieval performance in scopolamine impaired rhesus monkey. Psychopharmacology, 231(3), pp. 511-519. (doi:10.1007/s00213-013-3260-0) (PMID:24051602)

Neale, S.A., Copeland, C.S., Uebele, V.N., Thomson, F.J. and Salt, T.E. (2013) Modulation of hippocampal synaptic transmission by the kynurenine pathway member xanthurenic acid and other VGLUT inhibitors. Neuropsychopharmacology, 38(6), pp. 1060-1067. (doi:10.1038/npp.2013.4) (PMID:23303071) (PMCID:PMC3629405)

Baker, J. et al. (2011) Identification and optimisation of novel sulfonamide, selective vasopressin V1B receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 21(12), pp. 3603-3607. (doi:10.1016/j.bmcl.2011.04.104)

Napier, S. et al. (2011) The discovery of novel 8-azabicyclo[3.2.1]octan-3-yl)-3-(4-chlorophenyl) propanamides as vasopressin V1A receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 21(10), pp. 3163-3167. (doi:10.1016/j.bmcl.2011.02.096)

Napier, S. E. et al. (2011) Synthesis and SAR studies of novel 2-(4-oxo-2-aryl-quinazolin-3(4H)-yl)acetamide vasopressin V1b receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 21(6), pp. 1871-1875. (doi:10.1016/j.bmcl.2010.12.081)

Brown, A. R. et al. (2011) Discovery and optimisation of a selective non-steroidal glucocorticoid receptor antagonist. Bioorganic and Medicinal Chemistry Letters, 21(1), pp. 137-140. (doi:10.1016/j.bmcl.2010.11.054) (PMID:21129964)

Spiga, F., Knight, D. M., Droste, S. K., Conway-Campbell, B., Kershaw, Y., MacSweeney, C. P., Thomson, F. J. , Craighead, M., Peeters, B. W.M.M. and Lightman, S. L. (2011) Differential effect of glucocorticoid receptor antagonists on glucocorticoid receptor nuclear translocation and DNA binding. Journal of Psychopharmacology, 25(2), pp. 211-221. (doi:10.1177/0269881109348175) (PMCID:PMC4984974)

Letourneau, J. J. et al. (2010) Identification and optimization of novel 2-(4-oxo-2-aryl-quinazolin-3(4H)-yl)acetamide vasopressin V3 (V1b) receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 20(18), pp. 5394-5397. (doi:10.1016/j.bmcl.2010.07.118)

Reid, M. et al. (2010) The discovery and SAR of indoline-3-carboxamides—A new series of 5-HT6 antagonists. Bioorganic and Medicinal Chemistry Letters, 20(12), pp. 3713-3716. (doi:10.1016/j.bmcl.2010.04.085)

Spiga, F., Harrison, L.R., Wood, S., Knight, D.M., MacSweeney, C.P., Thomson, F. , Craighead, M. and Lightman, S.L. (2009) Blockade of the V1b receptor reduces ACTH, but not corticosterone secretion induced by stress without affecting basal hypothalamic-pituitary-adrenal axis activity. Journal of Endocrinology, 200(3), pp. 273-283. (doi:10.1677/JOE-08-0421)

Spiga, F., Harrison, L. R., MacSweeney, C. P., Thomson, F. J. , Craighead, M. and Lightman, S. L. (2009) Effect of vasopressin 1b receptor blockade on the hypothalamic-pituitary-adrenal response of chronically stressed rats to a heterotypic stressor. Journal of Endocrinology, 200(3), pp. 285-291. (doi:10.1677/JOE-08-0425) (PMID:19074473)

Thomson, F. and Craighead, M. (2008) Innovative approaches for the treatment of depression: targeting the HPA axis. Neurochemical Research, 33(4), pp. 691-707. (doi:10.1007/s11064-007-9518-3) (PMID:17960478)

Spiga, E., Harrison, L.R., MacSweeney, C.P., Thomson, F.J. , Craighead, M. and Lightman, S.L. (2008) Blockage of the vasopressin V1b receptor prevents the chronic restraint-induced sensitization of the ACTH response to acute noise. European Neuropsychopharmacology, 18, S28. (doi:10.1016/S0924-977X(08)70034-8)

Spiga, F., Harrison, L. R., Wood, S. A., MacSweeney, C. P., Thomson, F. .J. , Craighead, M., Grassie, M. and Lightman, S. L. (2008) Effect of the glucocorticoid receptor antagonist Org 34850 on fast and delayed feedback of corticosterone release. Journal of Endocrinology, 196(2), pp. 323-330. (doi:10.1677/JOE-07-0503) (PMID:18252955)

Craighead, M., Milne, R., Campbell-Wan, L., Watson, L., Presland, J., Thomson, F. J. , Marston, H. M. and MacSweeney, C. P. (2008) Characterization of a novel and selective V1B receptor antagonist. Progress in Brain Research, 170, pp. 527-535. (doi:10.1016/S0079-6123(08)00440-8) (PMID:18655906)

Spiga, F., Harrison, L.R., Wood, S.A., Atkinson, H.C., MacSweeney, C.P., Thomson, F. , Craighead, M., Grassie, M. and Lightman, S.L. (2007) Effect of the glucocorticoid receptor antagonist Org 34850 on basal and stress-induced corticosterone secretion. Journal of Neuroendocrinology, 19(11), pp. 891-900. (doi:10.1111/j.1365-2826.2007.01605.x) (PMID:17927667)

Price, M. R. et al. (2005) Allosteric modulation of the cannabinoid CB1 receptor. Molecular Pharmacology, 68(5), pp. 1484-1495. (doi:10.1124/mol.105.016162) (PMID:16113085)

Thomson, F. J. , Jess, T. J., Moyes, C., Plevin, R. and Gould, G. (1997) Characterization of the intracellular signalling pathways that underlie growth-factor-stimulated glucose transport in Xenopus oocytes: evidence for ras- and rho-dependent pathways of phosphatidylinositol 3-kinase activation. Biochemical Journal, 325(3), pp. 637-643. (PMID:9271083)

Jess, T. J., Belham, C. M., Thomson, F. J. , Scott, P. H., Plevin, R. J. and Gould, G. (1996) Phosphatidylinositol 3′-kinase, but not p70 ribosomal S6 kinase, is involved in membrane protein recycling: Wortmannin inhibits glucose transport and downregulates cell-surface transferrin receptor numbers independently of any effect on fluid-phase endocytosis in fibroblasts. Cellular Signalling, 8(4), pp. 297-304. (doi:10.1016/0898-6568(96)00054-X) (PMID:8842531)

Livingstone, C. et al. (1996) Hormonal regulation of the insulin-responsive glucose transporter, GLUT4: some recent advances. Proceedings of the Nutrition Society, 55(1B), pp. 179-190. (doi:10.1079/PNS19960019) (PMID:8832790)

Thomson, F. j. , Moyes, C., Scott, P. H., Plevin, R. and Gould, G. W. (1996) Lysophosphatidic acid stimulates glucose transport in Xenopus oocytes via a phosphatidylinositol 3'-kinase with distinct properties. Biochemical Journal, 316(1), pp. 161-166. (PMID:8645200) (PMCID:PMC1217317)

Gould, G. W. , Cuenda, A., Thomson, F. J. and Cohen, P. (1995) The activation of distinct mitogen-activated protein kinase cascades is required for the stimulation of 2-deoxyglucose uptake by interleukin-1 and insulin-like growth factor-1 in KB cells. Biochemical Journal, 311(3), pp. 735-738. (PMID:7487926)

Thomson, F. J. and Clark, M. A. (1995) Purification of a phosphatidic-acid-hydrolysing phospholipase A2 from rat brain. Biochemical Journal, 306(1), pp. 305-309. (PMID:7864824)

Thomson, F.J. , Perkins, L., Ahern, D. and Clark, M. (1994) Identification and characterization of a lysophosphatidic acid receptor. Molecular Pharmacology, 45(4), pp. 718-723. (PMID:8183251)

Perkins, L. M., Ramirez, F. E., Kumar, C. C., Thomson, F. J. and Clark, M. A. (1994) Activation of serum response element-regulated genes by lysophosphatidic acid. Nucleic Acids Research, 22(3), pp. 450-452. (doi:10.1093/nar/22.3.450) (PMID:8127683) (PMCID:PMC523602)

Thomson, F.J. , Johnson, M.S., Mitchell, R. and Wolbers, B. (1994) Evidence for a role of phospholipase A2 in the mechanism of LHRH priming in rat anterior pituitary tissue. Journal of Endocrinology, 141(1), pp. 15-31. (doi:10.1677/joe.0.1410015) (PMID:8014598)

Thomson, F. J. and Clark, M. A. (1994) Purification of a lysophosphatidic acid-hydrolysing lysophospholipase from rat brain. Biochemical Journal, 300(2), pp. 457-461. (doi:10.1042/bj3000457) (PMID:8002951)

Thomson, F.J. , Johnson, M.S., MacEwan, D.J. and Mitchell, R. (1993) Oestradiol-17 modulates the actions of pharmacologically distinct forms of protein kinase C in rat anterior pituitary cells. Journal of Endocrinology, 136(1), pp. 105-117. (doi:10.1677/joe.0.1360105) (PMID:8429266)

Johnson, M.S., Thomson, F.J. , MacEwan, D.J. and Mitchell, R. (1993) The involvement of dihydropyridine-sensitive calcium channels in phorbol ester-induced luteinizing hormone and growth hormone release. Molecular and Cellular Endocrinology, 95(1-2), pp. 31-41. (doi:10.1016/0303-7207(93)90026-G) (PMID:7694878)

MacEwan, D. J., Mitchell, R., Johnson, M. S., Thomson, F. J. , Lutz, E. M., Clegg, R. A. and Connor, K. (1993) Evidence that protein kinase Cα has reduced affinity towards 1,2-dioctanoyl-sn-glycerol: the effects of lipid activators on phorbol ester binding and kinase activity. European Journal of Pharmacology: Molecular Pharmacology, 246(1), pp. 9-18. (doi:10.1016/0922-4106(93)90003-R)

Thomson, F. J. , Johnson, M. S., Mitchell, R., Wolbers, W.B., Ison, A. J. and MacEwan, D. J. (1993) The differential effects of protein kinase C activators and inhibitors on rat anterior pituitary hormone release. Molecular and Cellular Endocrinology, 94(2), pp. 223-234. (doi:10.1016/0303-7207(93)90171-F) (PMID:8224525)

Thomson, F. J. and Mitchell, R. (1993) Differential involvement of phospholipase A2 in phorbol ester-induced luteinizing hormone and growth hormone release from rat anterior pituitary tissue. Molecular and Cellular Endocrinology, 95(1-2), pp. 75-83. (doi:10.1016/0303-7207(93)90031-E) (PMID:8243810)

Johnson, M. S., Mitchell, R. and Thomson, F. J. (1992) The priming effect of luteinizing hormone-releasing hormone (LHRH) but not LHRH-induced gonadotropin release, can be prevented by certain protein kinase C inhibitors. Molecular and Cellular Endocrinology, 85(3), pp. 183-193. (doi:10.1016/0303-7207(92)90257-7) (PMID:1634016)

MacEwan, D. J., Mitchell, R., Thomson, F. J. and Johnson, M. S. (1991) Inhibition of depolarisation-induced calcium influx into GH3 cells by arachidonic acid: the involvement of protein kinase C. Biochimica et Biophysica Acta: Molecular Cell Research, 1094(3), pp. 346-354. (doi:10.1016/0167-4889(91)90096-G) (PMID:1911881)

Conference or Workshop Item

Eddins, D. et al. (2011) The glycine transporter 1 inhibitors RG1678 and ORG25935 attenuate a scopolamine-induced impairment in object retrieval performance in adult rhesus macaques. Society for Neuroscience Abstract Viewer and Itinerary Planner, 2011.

Morrow, J.A., Gilfillan, R., McAlpine, C., Neale, S.A., Porter, A., Smith, L.H. and Thomson, F. (2011) Functional characterization of structurally distinct classes of Glycine Transporter type 1 (GlyT1) inhibitors. Society for Neuroscience Abstract Viewer and Itinerary Planner, 2011.

Thomson, F. , Dunnigan, J., Gilfillan, R., Morrow, J.A. and Porter, A. (2011) Characterization of the receptor binding properties of structurally distinct classes of glycine transporter type 1 (glyt1) inhibitor. Society for Neuroscience Abstract Viewer and Itinerary Planner, 2011.

This list was generated on Fri Dec 6 02:39:29 2019 GMT.

Grants

Grants and Awards listed are those received whilst working with the University of Glasgow.

  • Experimental Therapeutic Support
    Beatson West of Scotland Cancer Centre
    2018 - 2019
     
  • TASTER (TArgeting STEm cell Resistance) - Defining leukaemic cell clonal architecture to inform and monitor drug responses in the TASTER CML Phase II Clinical Trial
    Cancer Research UK
    2018 - 2019
     
  • Developing Leukaemic Biomarkers to Enable Personalised CNS-directed Therapy
    UK Children's Cancer Study Group
    2017 - 2020
     
  • CDD Biomarkers Tender
    Cancer Research UK
    2017 - 2019
     
  • Glasgow ECMC
    Cancer Research UK
    2017 - 2019
     
  • Glasgow ECMC
    Chief Scientist Office
    2017 - 2018
     
  • PARADIGM-2: Olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in newly diagnosed glioblastoma stratified by MGMT status: 2 parallel phase I studies
    Cancer Research UK
    2016 - 2020
     
  • A Phase Ib/IIa clinical trial of FAK inhibitor VS6063 in combination with anti-PD1/PDL1 therapy
    Cancer Research UK
    2016 - 2020
     
  • HIPROC
    NHS Greater Glasgow and Clyde
    2015 - 2018
     
  • M190 Bioven Costs
    NHS Greater Glasgow and Clyde
    2014 - 2015